

## METHOD AND APPARATUS FOR DETECTION AND TREATMENT OF RESPIRATORY DISORDER BY IMPLANTABLE DEVICE

The present application claims priority to US Provisional patent application 60/546,551  
5 filed 20 February 2004.

### 1.0 FIELD OF THE INVENTION

The invention relates to the detection and treatment of respiratory disorders by  
implantable electrical and/or electro-mechanical devices.

### 2.0 BACKGROUND

Nasal CPAP treatment of Sleep Disordered Breathing (SDB), for example as taught by  
Sullivan in US Patent 4,944,310 has become the standard. However, other techniques are  
known. Uvulopalatopharyngoplasty (UPPP) is a surgical procedure for the treatment of  
15 severe Obstructive Sleep Apnea (OSA). In UPPP, soft tissue on the back of the throat and  
soft palate (the uvula) is removed. Oral Mandibular Advancement Devices are dental  
appliances used to treat patients with Obstructive Sleep Apnea (OSA) and Upper Airway  
Resistance Syndrome (UARS). They look similar to mouth guards used in sports. Other  
techniques involve electrical stimulation.

US Patent 6,636,767 describes how an electrode is placed in stimulating contact with an  
airway passage-controlling muscle of the patient. The electrode is energized to contract  
the muscle and alter the airway passage.

25 However some researchers have noted (Guilleminault et al. Chest 1995 **107**:67-73) that  
"The results obtained by us and others do not, at this time, give convincing support for  
the use of electrical stimulation using submental surface or intraoral electrodes as a viable  
approach for effective control of obstructive sleep apnea syndrome symptoms."

30 It is known that central apnea and obstructive apnea can be discriminated by flow and  
effort sensors. See for example US Patents 6,675,797; 6,029,665; and 6,445,942.

It is an object of the invention to provide improved detection and treatment of respiratory disorders using implanted devices.

### 3.0 SUMMARY OF THE INVENTION

5 In accordance with a first aspect of the invention, treatment of a respiratory disorder utilises afferent nerve stimulation.

In accordance with a second aspect of the invention, treatment of a respiratory disorder utilises efferent nerve stimulation.

10

In accordance with another aspect of the invention, upper airway muscle tone is indirectly stimulated.

15 In accordance with another aspect of the invention, baseline treatment is initiated when the patient is asleep in order to achieve an increased background tone of upper airway muscles to prevent airway collapse.

In accordance with another aspect of the invention, treatment is initiated or increased above baseline treatment when obstructive sleep apnea is detected.

20

In accordance with another aspect of the invention, respiratory disorders are detected with the use of an implanted device.

25 In accordance with another aspect of the invention, open and closed airway (also called, central and obstructive) apneic events are distinguished by a combination of implanted electrodes and acoustic transducers.

### 4.0 BRIEF DESCRIPTION OF THE DRAWING

30

Fig. 1 shows method for detection and treatment of respiratory disorders using implantable devices.

## 5.0 DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

### 5.1 Treatment

For treatment of detected Obstructive Sleep Apnea (OSA), one method is electrical stimulation of afferent nerves, the objective of which is to indirectly cause an increase of the tone of upper airway muscles normally involved with maintenance of upper airway patency. In OSA, it is known that tone of these upper airway muscles typically decreases, contributing to a collapse and obstruction of the airway. Typically during wakefulness in patients with OSA, reflexes work to maintain tone in upper airway muscles thereby preventing airway collapse. The object of the present method is to substitute or enhance this reflex mechanism during sleep, thereby restoring or maintaining airway patency. The site of electrical stimulation is within or adjacent to the genioglossus muscle or in the vicinity of the hypoglossal motor nucleus or excitatory afferent nerve pathways leading to this structure. The amplitude, frequency and pulse width of electrical stimulation is controlled such that sufficient stimulation of afferent nerves is achieved without significant stimulation of efferent nerves, and without eliciting arousal from sleep. This stimulation of afferent nerves thus influences the patient's own intrinsic control system which modulates upper airway tone. The electrical stimulation of afferent nerves typically consists of trains of electrical pulses, for example; 0.1 mA amplitude, 0.1 ms duration, train length of 10-30 pulses repeated every 1 minute. This level is defined as 1 unit of stimulation.

A second method for stimulation of afferent nerves is by using mechanical stimulation. A mechanical element, for example a piezo-electric element, is implanted at a site in the vicinity of the upper airway, for example, within or adjacent to the base of the genioglossus muscle. The element is electrically connected to the controller of the implanted device. The controller elicits vibration of the mechanical element by sending an electrical signal. Vibration of the element elicits stimulation of mechanoreceptor

afferent nerve endings within the upper airway. Stimulation of these mechanoreceptors provides an excitatory input into the patient's intrinsic control system of the upper airway, thereby increasing tone of upper airway muscles and hence restoring or maintaining airway patency. The amplitude, frequency and duration of the mechanical stimulation are controlled such that sufficient stimulation of afferent nerves is achieved without sensory stimulation sufficient to cause arousal from sleep. The mechanical stimulation of afferent nerves would typically be achieved by a period of several seconds of vibration at frequencies in the range of 10-50 Hz, and is tuned to the frequency at which the target receptors are most sensitive. The repetition rate of the stimulation is controlled according to the detected state of the airway.

For either electrical or mechanical stimulation, the level of stimulation depends on 2 factors: 1) sleep state; 2) state of upper airway. When the patient is awake, no treatment is delivered. When the patient is asleep, a baseline treatment is delivered which has the objective of increasing the background tone of the upper airway muscles such that it is similar to the tone during the awake state. This is designed to pre-emptively reduce the incidence of airway collapse. When the patient is asleep and airway obstruction is detected, treatment above the level of the baseline treatment is delivered which has the objective of restoring airway patency. Sleep state is determined by a combination of time of day and postural state, for example when the patient is supine and the time of day is coincident with the patient's normal sleeping time, sleep state is determined as asleep. Time of day is determined by a real time clock within the implanted device and postural state by a position sensor, also contained within the implanted device. When the sleep state is asleep, the baseline level of treatment is initiated. When the sleep state is asleep and obstruction is detected, the level of treatment is increased and maintained until such time as airway obstruction is no longer detected, as follows:

<b>Sleep State/ Airway State</b>	awake	asleep	Asleep plus airway obstruction
--------------------------------------	-------	--------	-----------------------------------

Treatment level	No treatment	Baseline treatment of 0-5 units	Incremental above baseline of 1-10 units
-----------------	--------------	------------------------------------	--

An example of a methodology as described is illustrated in Figure 1.

5

## 5.2 Detection of respiratory disorders via implanted electrodes

### 5.2.1 Impedance

Implanted electrodes are ideally placed one either side of the thoracic cavity. eg one  
10 electrode is placed in the left sub pectoral region and a second electrode in the right sub  
pectoral region. One of these electrodes could be incorporated into the metallic case of an  
implanted device.

The transthoracic impedance is measured by emitting high frequency (eg 20Hz) electrical  
15 pulses (compared with respiration or heart rate) that have amplitude and duration below  
the level needed to stimulate excitable tissue.

Typically current pulses of 1 mA amplitude and 15 micro second duration are emitted at a  
20 20 Hz. This level of energy is well below the level required to stimulate excitable tissue.

20

The impedance changes are calculated by measuring current & voltage and calculating  
impedance via Ohm's Law. Impedance changes are correlated with thorax movements.  
Patterns of movement are detected and used to indicate a variety of respiratory disorders  
such as Obstructive Apnea, central apnea, Cheyne-Stokes respiration (CS-R).

25

To detect impedance changes the instantaneous transthoracic impedance signal is  
compared to a baseline reference. eg the baseline reference is a continuously updated  
average of the most recent 30 minutes of the transthoracic impedance signal.

The changes the transthoracic impedance signal are analysed in order to determine the state of respiration as follows:

Respiration type	Transthoracic impedance
Normal respiration – no SDB	rhythmic variations at a rate of between 6 and 25 per minute; this rate averaged over; eg 2 minutes. Similarly an amplitude reference for 'normal breathing' is also derived; eg average amplitude of rhythmic variations over 30 minutes.
Obstructive	Marked reduction of amplitude as compared to the above reference; eg reduction of 30% or more; for at least 10 seconds.
Central apnea	first derivative of the impedance signal = essentially zero; no rhythmic variations for a period of 10 seconds or more
CSR	Derive the envelope of the rhythmic variations. Crescendo-decrescendo pattern denoted by a rhythmic variation in the envelope with a period of typically between 40 and 120 seconds or other classifier system.

5

### 5.2.2 Impedance and acoustic transducers

A method for measuring airflow in an implantable device is by use of an acoustic transducer inside the device, such as a microphone, or from a transmitted signal from an external device in communication with the implantable device. Analysis of the frequency and amplitude of the sound can be used to deduce relative airflow. In addition, snoring,

10

which is indicative of a partial obstruction of the upper airway can be detected. It is known that snoring is frequently a precursor of obstructive apnea.

5 A method for indicating thoracic movement is by measuring the electrical impedance between two or more implanted electrodes.

By a combination of methods for deducing airflow and thoracic movement, it is possible to discriminate between central and obstructive apnea in an implantable device. For example, if thoracic movements are detected without corresponding airflow, it is possible  
10 to deduce that there is obstructive apnea occurring. If there is no airflow and no thoracic movements for a specified period, it is possible to deduce that there is central apnea.